| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
22039 |
| Drug |
Daratumumab |
| Brand |
Darzalex® |
| Indication |
In combination with lenalidomide (Revlimid®) and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant |
| Rapid review commissioned |
30/05/2022 |
| Rapid review completed |
30/06/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab in combination with lenalidomide and dexamethasone for this indication compared with the current standard of care |
| Full pharmacoeconomic assessment commissioned by HSE |
27/07/2022 |
| Pre-submission consultation with Applicant |
11/10/2022 |
| Full submission received from Applicant |
09/01/2023 |
